insights_auto
Why is ABVX down 2,78%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
76,90 €
arrow_downward
-2,78%(-2,20) 1D
16 ნოე, 17:35:03 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
79,00 €
High
80,05 €
Low
76,90 €
Mkt. cap
6,63 მლრდ.
Avg. vol.
109,70 ათ.
Volume
89,36 ათ.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 მლნ.
No. of employees
98
Open
79,00 €
High
80,05 €
Low
76,90 €
Mkt. cap
6,63 მლრდ.
Avg. vol.
109,70 ათ.
Volume
89,36 ათ.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 მლნ.
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
3 საათის წინ
Abivax shares slip back below €76.05, in the lower ranks of the SBF 120
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOმარკ დე გარიდელი | ჰარტმუტ ჯეი ერლიხი
Employees98
Founded4 დეკ. 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com